Deferiprone Taro

/ Taro

Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. Dose per kilogram body weight should be calculated to the nearest half tablet.
Please refer to the license holder for further details.

Monotherapy: Ttreatment of iron overload in patients over 6 years old with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Combination therapy: Combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.

* Hypersensitivity to the active substance or to any of the excipients
* History of recurrent episodes of neutropenia
* History of agranulocytosis
* Pregnancy
* Breast-feeding
* Pharmaceutical agents with established associations to neutropenia or the potential to induce agranulocytosis.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.